3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
4
Waldenstrom Macroglobulinemia
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, B-Cell
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
7
acalabrutinib
4
pirtobrutinib
3
fludarabine
3
Rituximab
3
fludarabine phosphate
2
Vincristine
2
Melphalan
2
Doxorubicin
2
thymoglobulin
1
obinutuzumab
1
idecabtagene vicleucel
1
ibrutinib
1
Stem Cell Transplantation
1
Prednisone
1
Prednisolone
1
Mycophenolic Acid
1
Mesna
1
Immunotherapy, Adoptive
1
Filgrastim
1
Diet
1
Bone Marrow Transplantation
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Leukemia, B-Cell
×
ARQ531
×
Clear all
NCT04728893
2026-05-26
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2
Recruiting
490 enrolled